RECOVERY & TISSUE REPAIR / FAQ
Clinical Answers to Common Questions
Direct, citation-anchored responses to the questions that come up most often about these four recovery research peptides.
What is KLOW peptide?
KLOW is a co-formulated, lyophilized research blend of four peptides: KPV (the anti-inflammatory tripeptide derived from alpha-MSH), GHK-Cu (a copper-binding tripeptide studied for matrix repair), BPC-157 (a 15-amino-acid gastric pentadecapeptide studied for angiogenesis and cytoprotection), and TB-500 (the synthetic actin-binding fragment of thymosin beta-4). It is not a single chemical entity; the four components are co-dissolved at fixed mass ratios in one research vial. No FDA-approved or pharmacopeial KLOW product exists [1].
What is KLOW peptide used for?
In the research context, KLOW is discussed as a blend that theoretically addresses multiple steps of the tissue-repair cascade simultaneously: cytokine suppression (KPV via NF-kB/MAPK), matrix remodeling (GHK-Cu via collagen synthesis), vascular supply (BPC-157 via VEGFR2 angiogenesis) and cytoskeletal mobilization (TB-500/thymosin beta-4 via G-actin sequestration) [1][5][4][10][11]. The critical qualification is that no controlled study has tested the four-peptide blend itself against monotherapy, any subset, or placebo. Every research claim for the blend is a mechanistic extrapolation from single-component literature [1].
Where do you inject KLOW peptide?
This desk does not advise on human injection sites, protocols, or use. KLOW is supplied for laboratory and research use only; it is not formulated, labeled or intended for human administration. Individual components have been studied at defined doses in specific animal models — for example, BPC-157 intramuscularly and intragastrically in rats [13], thymosin beta-4 intravenously in humans [15] — but those study routes are not recommendations. Consult a licensed clinician for any clinical question.
How much KLOW peptide per day?
This desk does not recommend doses. No controlled human study has established a safe or effective dose of the KLOW blend, or of any of its four components as a blend. BPC-157 has a very short elimination half-life (under 30 minutes in rats and dogs), and the two tripeptide components clear even faster [12]. Community dosing protocols for this blend have no basis in controlled human pharmacokinetic or pharmacodynamic data. This is a research chemical; we report animal study doses as reported in the literature, not as guidance.
What is the Wolverine peptide blend?
Wolverine is a two-peptide research blend pairing BPC-157 (Body Protection Compound 157) with TB-500 (the Ac-LKKTETQ fragment of thymosin beta-4). The mechanistic rationale is that BPC-157 supplies an angiogenic signal via VEGFR2 [10] while TB-500/thymosin beta-4 supplies an actin-sequestration signal that drives cell migration [11]. Despite its prevalence in research-peptide discussions, no peer-reviewed study has been published testing these two compounds together in any model; the combination is a theoretical extrapolation [8].
What is BPC-157 and TB-500?
BPC-157 is a 15-amino-acid synthetic peptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protein in human gastric juice; it is studied for cytoprotection and angiogenesis via VEGFR2 [10]. TB-500 is a 7-amino-acid synthetic peptide (Ac-LKKTETQ) corresponding to the actin-binding region of thymosin beta-4; it is studied for actin regulation and cell migration [11]. Both are unapproved research peptides, and both are WADA-prohibited. TB-500 is the short fragment of a much larger protein; most of its cited efficacy data were generated with the full-length protein, not the 7-mer [1].
What is the BPC-157 and TB-500 blend used for in research?
In research discussions the BPC-157 + TB-500 (Wolverine) blend is described as a tissue-repair combination: BPC-157 for its angiogenic and cytoprotective effects [10] and TB-500/thymosin beta-4 for its actin-driven cell migration and wound-healing effects [11]. A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies, found "no clinical safety data," and made no mention of TB-500 or combination use — underscoring that the blend itself has no controlled research evidence [8].
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The combination argument is that the two peptides address different, largely non-overlapping mechanisms in the repair cascade: BPC-157 drives new vessel formation (angiogenesis via VEGFR2/Akt/eNOS) [10], while TB-500/thymosin beta-4 regulates the actin cytoskeleton that underlies cell migration and re-epithelialization [11]. The logic is sound at the mechanistic level. What is missing is any controlled study testing this combination — no defined dose ratio, no comparison to monotherapy, no human efficacy data [8].
What does BPC-157 do in the body?
In animal models, BPC-157 is described as a cytoprotective and regenerative peptide whose repair effects trace most consistently to angiogenesis: it makes blood-vessel cells more responsive to the VEGFR2 vessel-growth signal, increasing new vessel density and accelerating blood-flow recovery in ischemic tissue [10]. It has accelerated healing in rat models of gastric ulcers [13] and transected tendon [6]. Almost all of this is preclinical; human evidence is limited to three small pilot studies [9].
Is BPC-157 a growth hormone?
No. BPC-157 is not growth hormone and is not a growth-hormone analog. It is a synthetic 15-amino-acid peptide from gastric juice. One point of potential confusion: in tendon fibroblasts, BPC-157 has been described as sensitizing the growth-hormone receptor, which may amplify the effect of the body's own growth hormone. Sensitizing a receptor is not the same as being the hormone. BPC-157 does not replace or function as growth hormone [9].
Does BPC-157 work immediately?
The peptide clears quickly. Formal pharmacokinetic work in rats and dogs found an elimination half-life under 30 minutes, with rapid breakdown into small fragments that re-enter normal amino-acid metabolism [12]. Whether any healing effect manifests quickly in animals is a separate question — healing studies are measured over days to weeks, not minutes. There are no controlled human data on timing of any BPC-157 effect. This desk does not advise on use or timing.
Does BPC-157 damage the liver?
The available data do not show liver harm, but the data are very thin. In the 2025 first-in-human IV safety pilot, BPC-157 up to 20 mg in two healthy adults produced no measurable changes in hepatic biomarkers and no adverse events [2]. Two people in a safety pilot is not a liver-safety study. A 2025 narrative review stresses that without long-term, large-sample human safety data, the safety profile is genuinely unknown [9]. Nothing here is medical advice.
What is TB-500?
TB-500 is a synthetic 7-amino-acid peptide, Ac-LKKTETQ, corresponding to the actin-binding region (residues 17-23) of thymosin beta-4 (Tβ4), the endogenous 43-residue G-actin sequestering protein [16]. The "TB" in its name refers to thymosin beta. In commerce and anti-doping science, "TB-500" denotes the short fragment; most published efficacy research uses the full-length protein, which is roughly five times larger [1]. TB-500 is a research peptide with no approved therapeutic indication and no completed controlled human trials for any indication.
What does TB-500 stand for and what does TB stand for in TB-500?
"TB" stands for thymosin beta. TB-500 is named as the synthetic fragment of the thymosin beta-4 protein. The "500" designation reflects its origin as a specific research formulation of the Ac-LKKTETQ actin-binding fragment. The parent protein, thymosin beta-4, is a 43-amino-acid endogenous peptide that is the primary intracellular G-actin sequestering molecule, establishing the cytoskeletal dynamics underlying cell migration and wound healing [11][16].
What is TB-500 used for in research?
In research, TB-500 — and more often full-length thymosin beta-4 — is studied for tissue repair through actin regulation: cell migration, new blood-vessel growth, reduced scarring, and anti-inflammatory signaling, across dermal-wound, corneal, cardiac and CNS models [11]. A human Phase 1 study of full-length Tβ4 in 40 volunteers focused on safety and pharmacokinetics, found it well tolerated to 1260 mg IV [15]. A rat stroke dose-response study showed neurological recovery at 2 and 12 mg/kg but not at 18 mg/kg — a non-monotonic result [14]. No completed controlled clinical trial of the TB-500 fragment exists for any indication [1].
Does TB-500 work for muscle tears and recovery from exercise?
There is no controlled human evidence that the TB-500 fragment helps muscle tears or exercise recovery. The mechanistic rationale comes from thymosin beta-4's role in cell migration and repair [11], but a 2026 Sports Medicine review covering unapproved peptides for musculoskeletal injury concluded that favorable animal results have not been matched by rigorous human safety or efficacy data, and that these compounds operate largely outside regulatory oversight [1]. Notably, in a muscular-dystrophy mouse model, chronic Tβ4 increased regenerating fibers but did not improve muscle strength [11]. TB-500 is also WADA-prohibited [1].